|
|
|
|
|
|
|
|
abstract
Distribution and case-fatality ratios by cell-type for ovarian carcinomas: A 22-year series of 562 patients with uniform current histological classification
Highlights
- •
- Among 562 ovarian cancers classified by cell-type, high grade serous carcinoma and its variants accounted for 85% of tumor deaths
- •
- Reproducibility of cell-type designation among gynecologic pathology experts was excellent
- •
- 1.7% of type II tumors (high grade serous carcinomas and variants) were FIGO stage I with comprehensive surgical staging
Background
Ovarian carcinoma is comprised of several different cell types
reflecting different clinicopathologic features. Pathologic criteria for
distinguishing cell types have evolved, and therefore non-contemporary
literature on ovarian cancer may have limited current relevance. A new
dualistic model of pathogenesis that distinguishes type I (endometrioid,
mucinous, clear cell and low grade serous carcinomas) from type II
(high grade serous carcinomas and carcinosarcomas) tumors has become
widely accepted.
Methods
A
cohort of 562 patients with invasive ovarian carcinoma from a large
community hospital practice was reviewed. Cell type, FIGO stage,
mortality and interpathologist diagnostic reproducibility were analyzed.
Results
Advanced
stage ovarian carcinomas were type II in 86% of cases while low stage
tumors were most often type I. Only 1.7% of type II tumors were
confirmed to be stage I with comprehensive surgical staging. Type II
tumors accounted for 85% of deaths, and clear cell carcinomas, 5% of
deaths. Cell type-specific case-fatality ratios for type II tumors were
62% and 79% for high grade serous carcinoma and carcinosarcoma,
respectively. For type I tumors, case-fatality ratios were 38%, 36%, 27%
and 13% for low grade serous, clear cell, endometrioid and mucinous
carcinomas, respectively. The kappa value for diagnostic reproducibility
among 3 gynecologic pathologists was 0.83.
Conclusions
Current
diagnostic criteria confirm that high grade serous carcinoma and
carcinosarcoma account for the vast majority (85%) of ovarian cancer
deaths. Cell type designation is highly reproducible among gynecologic
pathologists. Type II tumors are rarely stage I (< 2%) when
comprehensively staged by a gynecologic oncologist.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.